Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases Photys and Novo Nordisk established a research collaboration to discover a new class of medicine for cardiometabolic diseases.

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled in active-controlled trial...

Cardiometabolic Diseases Market Size ($121,804.49Mn by 2028) Lead by Cardiovascular Disease (3.9% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cardiometabolic Diseases Market: Key InsightsAccording to our new research study on Cardiometabolic Diseases Market Size and Forecast to 2028 - COVID-19...